Qiagen (QGEN) investor relations material

Opening remarks and agenda

• Meeting opened by the Chairman, with Supervisory and Managing Board members, auditors, and legal counsel present.

• Procedural details included live webcast, English as the official language, and confirmation of voting rights and attendance.

• The meeting was held on June 24, 2026, in Venlo, the Netherlands, with a comprehensive agenda covering financial, strategic, and governance topics.

Financial performance review

• 2025 sales reached $2.09 billion, up 6% reported and 5% at constant exchange rates, with adjusted operating income margin rising to 29.5%.

• Adjusted EPS grew 9% to $2.38, exceeding targets; adjusted diluted EPS reached $2.40 (CER); operating cash flow was $654 million.

• Growth pillars delivered $1.49 billion in sales, with QIAstat-Dx and QuantiFERON as key drivers.

• R&D expenses were 9% of sales; sales and marketing expenses declined, while general admin costs rose slightly due to IT investments.

• Q1 2026 showed mixed sales trends, with a sales guidance miss due to a slowdown in TB immigration testing in the U.S., but maintained profitability and EPS outlook.

Board and executive committee updates

• Significant renewal of the Supervisory Board, with seven of eight members joining since 2021.

• New Supervisory Board members with significant industry experience were welcomed, including Mark P. Stevenson and Robert McMahon.

• Two new members and six reappointments to the Supervisory Board were unanimously approved.

• Dr. Metin Colpan, co-founder, concluded his service and was named Honorary Chairman.

• Reappointments of Managing Board members Thierry Bernard and Roland Sackers confirmed.